<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>leukemia immunotherapy &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/leukemia-immunotherapy/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 26 Jan 2026 19:39:09 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>leukemia immunotherapy &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>CXCR4 Boosts Memory, Limits Exhaustion in CAR-T Cells</title>
		<link>https://bioengineer.org/cxcr4-boosts-memory-limits-exhaustion-in-car-t-cells/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 26 Jan 2026 19:38:45 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[CAR-T cell engineering]]></category>
		<category><![CDATA[CAR-T cell memory]]></category>
		<category><![CDATA[CAR-T cell memory enhancement]]></category>
		<category><![CDATA[Cellular immunotherapy enhancement]]></category>
		<category><![CDATA[CXCR4 in immunotherapy]]></category>
		<category><![CDATA[CXCR4 signaling]]></category>
		<category><![CDATA[durable leukemia targeting]]></category>
		<category><![CDATA[leukemia immunotherapy]]></category>
		<category><![CDATA[T cell exhaustion]]></category>
		<category><![CDATA[T cell exhaustion prevention]]></category>
		<guid isPermaLink="false">https://bioengineer.org/cxcr4-boosts-memory-limits-exhaustion-in-car-t-cells/</guid>

					<description><![CDATA[In the relentless quest to harness the immune system’s power to combat cancer, chimeric antigen receptor T cell (CAR-T) therapy has emerged as a transformative force in oncology. Yet, despite remarkable initial successes, durable remission remains a challenge in many patients due to T cell exhaustion. A recent breakthrough study led by Itoh-Nakadai and colleagues, [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">321251</post-id>	</item>
		<item>
		<title>Breakthrough Discovery: How Leukemia Cells Evade the Immune System Uncovered</title>
		<link>https://bioengineer.org/breakthrough-discovery-how-leukemia-cells-evade-the-immune-system-uncovered/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Fri, 03 Oct 2025 09:32:21 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[AML immune evasion]]></category>
		<category><![CDATA[cancer stem cells]]></category>
		<category><![CDATA[CRISPR/Cas9 targeting]]></category>
		<category><![CDATA[leukemia immunotherapy]]></category>
		<category><![CDATA[SLAMF6 protein]]></category>
		<guid isPermaLink="false">https://bioengineer.org/breakthrough-discovery-how-leukemia-cells-evade-the-immune-system-uncovered/</guid>

					<description><![CDATA[A groundbreaking study from Lund University in Sweden has unveiled a novel mechanism by which acute myeloid leukemia (AML) cells evade the immune system, opening promising avenues for targeted immunotherapy. AML remains a formidable adversary in oncology, with survival rates stubbornly low despite advances in treatment. This new research illuminates a previously unknown pathway that [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">275424</post-id>	</item>
	</channel>
</rss>
